Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Eli Lilly · Phase 2 · Not yet recruiting · Enrollment 224

NCT06732245

ArmPopulationDoseWeeksEstimandWeight change
Placebo Comparator: PlaceboObesity or overweightn/r4n/rn/r
Placebo + Tirzepatide 5 mgObesity or overweight5 mg4n/rn/r
Placebo + Tirzepatide 10 mgObesity or overweight10 mg4n/rn/r
NA-931 60mg to NA-931 150 mg + no TirzepatideObesity or overweight150 mg4n/rn/r
NA-931 60 mg + Tirzepatide 5 mgObesity or overweight5 mg4n/rn/r
NA-931 120 mg + Tirzepatide 5 mgObesity or overweight5 mg4n/rn/r
NA-931 150 mg + no TirzepatideObesity or overweight150 mg4n/rn/r
NA-931 150 mg + Tirzepatide 2.5 mgObesity or overweight2.5 mg4n/rn/r
NA-931 150 mg + Tirzepatide 5 mgObesity or overweight5 mg4n/rn/r